Protagenic Therapeutics, Inc.\new

PTIX

Protagenic Therapeutics, Inc.\new

PTIX

Insider Sentiment (TTM):

Last Purchase:2023-10-12Last Sale:-Shares Purchased (TTM):0Shares Sold (TTM):0

Institutional Sentiment:

As of:2026-03-31Institutional Shares Owned:41,924Shares Outstanding:1,934,878Institutional Ownership Pct.:2.17%

Earnings Market Reaction:

Filing Date:2026-08-19Price on Filing Date:N/APrevious Close:N/A% Change:N/A

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Financial Statements

10‑Q10‑K

Values in Millions ($)	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Assets
Assets Current
Cash	1	2	2	3	1	2	1	1	1	1	0
Marketable Securities Current	-	-	-	-	-	-	-	-	2	3	5
Prepaid Expense Current	0	0	0	0	0	0	0	0	0	0	0
Value Added Tax Receivable Current	-	-	0	0	-	-	-	-	-	-	-
Inventory Net	-	-	0	0	-	-	-	-	-	-	-
Assets Current	1	2	2	3	1	2	1	1	2	4	5
Assets Noncurrent
Property Plant And Equipment Net	0	0	0	0	0	0	0	0	0	0	0
Intangible Assets Net Excluding Goodwill	2	-	2	2	-	-	-	-	-	-	-
Assets Noncurrent	2	-	2	2	-	-	-	-	-	-	-
Assets	3	4	4	5	1	2	2	1	3	4	5
Liabilities And Stockhold…
Liabilities
Liabilities Current
Notes Payable Current	-	-	3	3	-	-	-	-	-	-	-
Accounts Payable Current	1	-	2	2	-	-	-	-	-	-	-
Accrued Liabilities Current	0	-	0	0	-	-	-	-	-	-	-
Derivative Liabilities Current	-	-	1	4	-	-	-	-	-	-	-
Loans Payable Current	-	-	1	1	-	-	-	-	-	-	-
Liabilities Current	1	1	7	10	1	1	1	1	0	1	1
Liabilities	1	1	7	10	1	1	1	1	0	1	1
Stockholders Equity
Common Stock Value	0	0	0	0	0	0	0	0	0	0	0
Additional Paid In Capital	7	7	7	7	38	37	36	35	35	35	34
Retained Earnings Accumulated Deficit	-5	-4	-9	-11	-38	-36	-35	-34	-33	-31	-29
Accumulated Other Comprehensive Income Loss Net Of…	-	-	-	-	-0	-0	-0	-0	-0	-0	-1
Accumulated Other Comprehensive Income Loss Foreig…	-0	-	-0	-0	-	-	-	-	-	-	-
Stockholders Equity	2	3	-2	-5	-0	1	-2	1	2	4	4
Liabilities And Stockholders Equity	3	4	4	5	1	2	2	1	3	4	5
Preferred Stock Par Or Stated Value Per Share	0	0	0	0	0	0	0	0	0	0	0
Preferred Stock Shares Authorized	2	2	2	20	20	20	20	20	20	20	20
Preferred Stock Shares Issued	0	0	0	0	0	0	0	0	0	0	0
Preferred Stock Shares Outstanding	0	0	0	0	0	0	0	0	0	0	0
Common Stock Par Or Stated Value Per Share	0	0	0	0	0	0	0	0	0	0	0
Common Stock Shares Authorized	100	100	100	100	100	100	100	100	100	100	100
Common Stock Shares Issued	2	2	2	2	1	7	5	4	4	4	4
Shares Outstanding	2	2	2	2	1	7	5	4	4	4	4

Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Start free trial

Custom Table

10‑Q10‑K

0/5

Search a metric to start building a table

Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Start free trial

Interactive Financial Visualizations

10‑Q10‑K

Stock Price:

OnOff

Transformations:

0/1

Search a metric to start building a visual

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Earnings Market Reaction

10‑Q10‑K

Fiscal Year	Q1 1 Month	Q1 2 Month	Q1 3 Month	Q2 1 Month	Q2 2 Month	Q2 3 Month	Q3 1 Month	Q3 2 Month	Q3 3 Month	Q4 1 Month	Q4 2 Month	Q4 3 Month
2026	-	-	-	-	-	-	-	-	-	-	-	-
2025	3.13%	-1.42%	-22.51%	25.89%	90.02%	28.98%	-46.64%	-73.54%	-82.06%	-	-	-
2024	-24.46%	-38.63%	-55.76%	18.71%	0.00%	-4.40%	-21.85%	-26.77%	-46.60%	11.79%	74.36%	30.40%
2023	-	-	-	-	-	-	-3.98%	11.11%	13.45%	-20.40%	-10.34%	-42.53%
Earnings Market Reaction data beyond 3 years is for subscribers only. Unlock the full earnings market reaction history Start 7-day free trial

Subscribe to unlock 17+ years of financial data and 90+ calculated metrics

Start 7-day free trial

Subscribe to unlock 17+ years of data and 90+ calculated metrics

Start free trial

Performance and Valuation Metrics

Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.

Metrics	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Liquidity Ratios
Current Ratio	0.66	1.50	0.34	0.29	0.86	2.00	1.80	2.03	5.53	6.41	4.20
Quick Ratio	0.53	1.46	0.33	0.29	0.81	1.95	1.34	1.37	5.43	6.19	4.12
Working Capital	-362.74K	511.11K	-4.52M	-6.85M	-148.80K	940.11K	633.39K	694.33K	2.02M	3.54M	4.10M
Leverage & Debt
Debt to Equity	0.62	0.39	-2.85	-2.06	-12.19	0.93	-0.32	0.85	0.21	0.18	0.31
Interest Coverage TTM	-43.52	-59.95	-93.30	-17.79	-22.66	-23.88	-19.77	-135.01	-72.31	-42.04	-31.32
Debt Ratio	0.38	0.28	1.54	1.94	1.09	0.48	0.52	0.46	0.17	0.15	0.24
Efficiency & Turnover
Asset Turnover TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Per Share Metrics
Diluted EPS TTM	0.21	-0.04	-1.55	-3.13	-10.02	-1.13	-0.80	-1.15	-18.96	-1.15	-0.91
Free Cash Flow Per Share TTM	-1.63	-1.32	-2.67	-1.96	-7.04	-0.87	-0.63	-1.16	-16.23	-0.89	-0.65
Dividend Per Share TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Growth Metrics
Net Income Growth (1Y)	-107.21%	-98.21%	-30.51%	12.98%	-12.75%	10.50%	9.72%	48.26%	106.31%	40.64%	2.11%
EPS Growth (1Y)	-102.08%	-96.24%	93.78%	171.44%	-47.17%	-2.03%	-11.93%	44.51%	2,711.90%	39.78%	1.88%
Valuation Metrics
P/E TTM	1.88	-15.99	-0.84	-1.10	-0.27	-6.08	-11.00	-10.99	-1.29	-12.04	-28.42
P/B TTM	0.41	0.60	-1.05	-1.35	-16.17	33.18	-19.17	71.03	3.64	16.42	26.87
Market Cap	709.60K	1.58M	2.52M	6.34M	1.43M	33.61M	47.36M	56.30M	7.76M	60.22M	111.57M
Enterprise Value	143.62K	69.88K	4.30M	7.62M	555.34K	31.78M	47.29M	55.37M	6.93M	58.93M	111.41M
Calculated Values
Free Cash Flow TTM	-2.95M	-3.07M	-5.17M	-3.63M	-3.69M	-4.28M	-3.41M	-5.16M	-5.14M	-3.85M	-2.80M
Net Debt	-565.99K	-1.51M	1.78M	1.28M	-872.96K	-1.84M	-71.40K	-924.60K	-831.78K	-1.29M	-153.33K
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
NCAV
NCAV Per Share TTM
Valuation Ratios
P/CF TTM
PEG Ratio
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
EV Revenue TTM
EV FCF TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Insider Transactions

2023-10-12Purchase

Owner: Arrow, Alexander K.

Title: Chief Financial Officer

Shares: 8,000

Price/Share: $0.81

Value: $6,480.00

Shares Owned: 45,815

Relationship: Officer

Ownership: Direct

2022-05-18Purchase

Owner: Arrow, Alexander K.

Title: Chief Financial Officer

Shares: 8,000

Price/Share: $0.72

Value: $5,760.00

Shares Owned: 151,260

Relationship: Officer

Ownership: Direct

2021-04-30Purchase

Owner: Arrow, Alexander K.

Title: Chief Financial Officer

Shares: 1,000

Price/Share: $2.29

Value: $2,290.00

Shares Owned: 120,260

Relationship: Officer

Ownership: Direct

Filed Date	Owner	Relationship	Title	Ownership	Purchase/Sale	No. Shares	Price Per Share	Value	Shares Owned	Document Type
2023-10-12	Arrow, Alexander K.	Officer	Chief Financial Officer	Direct	Purchase	8,000	0.81	$6,480.00	45,815	4
2022-05-18	Arrow, Alexander K.	Officer	Chief Financial Officer	Direct	Purchase	8,000	0.72	$5,760.00	151,260	4
2021-04-30	Arrow, Alexander K.	Officer	Chief Financial Officer	Direct	Purchase	1,000	2.29	$2,290.00	120,260	4
Additional insider transactions are for subscribers only. Unlock the complete Form 4 filing history Start 7-day free trial

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Institutional Ownership

No data available for chart

2026-03-31

2.17%

Inst. Shares: 41,924

Shares Outstanding: 1,934,878

2025-12-31

4.73%

Inst. Shares: 91,503

Shares Outstanding: 1,934,878

2025-09-30

4.48%

Inst. Shares: 82,911

Shares Outstanding: 1,849,389

2025-06-30

9.91%

Inst. Shares: 51,822

Shares Outstanding: 523,185

2025-03-31

30.27%

Inst. Shares: 158,392

Shares Outstanding: 523,185

Date	Institutional Shares Owned	Shares Outstanding	Institutional Ownership %
2026-03-31	41,924	1,934,878	2.17%
2025-12-31	91,503	1,934,878	4.73%
2025-09-30	82,911	1,849,389	4.48%
2025-06-30	51,822	523,185	9.91%
2025-03-31	158,392	523,185	30.27%
2024-12-31	132,063	4,899,953	2.70%
2024-09-30	151,979	5,395,604	2.82%
2024-06-30	141,053	4,443,243	3.17%
2024-03-31	99,426	316,804	31.38%
2023-12-31	94,445	4,344,580	2.17%
2023-09-30	77,659	4,330,959	1.79%
2023-06-30	78,466	4,330,959	1.81%
Additional institutional holders are for subscribers only. Unlock the complete Form 13F ownership history Start 7-day free trial

Protagenic Therapeutics, Inc.\new (PTIX) — SEC Financial Statements & Analysis

Protagenic Therapeutics, Inc.\new (PTIX) is a pharmaceutical preparations company, incorporated in DE. Protagenic Therapeutics, Inc.\new trades on OTC as: PTIX. Based on its latest SEC filing (Form 10-Q, period ending 2026-06-30), Protagenic Therapeutics, Inc.\new reported a Debt-to-Equity ratio of 0.62x, a Price-to-Book (P/B) ratio of 0.41x (TTM), at a market cap of $709.60K. Figures below are sourced from SEC EDGAR, as-filed.

Debt To Equity: 0.62x
P/B TTM: 0.41x
Market Cap: $709.60K

Data as of 2026-06-30 · Source: SEC EDGAR

Frequently Asked Questions

What industry is Protagenic Therapeutics, Inc.\new in?

Protagenic Therapeutics, Inc.\new (PTIX) operates in the Pharmaceutical Preparations industry.

What is PTIX's market cap?

Protagenic Therapeutics, Inc.\new (PTIX) has a market capitalization of $709.60K as of 2026-06-30.

What is PTIX's P/E ratio?

Protagenic Therapeutics, Inc.\new (PTIX)'s trailing twelve month P/E ratio is 1.88x as of 2026-06-30.

What exchange does PTIX trade on?

Protagenic Therapeutics, Inc.\new (PTIX) trades on the OTC.

Where is Protagenic Therapeutics, Inc.\new incorporated?

Protagenic Therapeutics, Inc.\new is incorporated in DE.